User:Mr. Ibrahem/Chlorpropamide

Mr. Ibrahem/Chlorpropamide
Clinical data
Pronunciation	klor proe' pa mide
Trade names	Diabinese, Glucamide, others
AHFS/Drugs.com	Monograph
MedlinePlus	a682479
License data	US FDA: Chlorpropamide;
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth
Drug class	1st generation sulfonylurea
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	>90%
Protein binding	90%
Metabolism	<1%
Elimination half-life	36 hours
Excretion	Kidney (glomerular filtration → reabsorption → tubular secretion)
Identifiers
	IUPAC name 4-chloro-N-(propylcarbamoyl)benzenesulfonamide;
Chemical and physical data
Formula	C10H13ClN2O3S
Molar mass	276.74 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	126 to 130 °C (259 to 266 °F)
	SMILES O=S(=O)(c1ccc(Cl)cc1)NC(=O)NCCC;
	InChI InChI=1S/C10H13ClN2O3S/c1-2-7-12-10(14)13-17(15,16)9-5-3-8(11)4-6-9/h3-6H,2,7H2,1H3,(H2,12,13,14) ; Key:RKWGIWYCVPQPMF-UHFFFAOYSA-N ;
	(verify)

Chlorpropamide, sold under the brand name Diabinese among others, is a medication used to treat type 2 diabetes.^[2] It is used together with diet and exercise.^[2] It is a second line treatment.^[2] It is taken by mouth.^[2]

Common side effects include headache, dizziness, numbness, abdominal discomfort, weight gain, and nausea.^[1]^[2] Other side effects may include low blood sugar and liver problems.^[1]^[2] Safety in pregnancy is unclear.^[2] It is a first generation sulfonylurea and works by increasing the release of insulin.^[2]^[1]^[3]

Chlorpropamide was approved for medical use in the United States in 1958.^[2] Commercial sale has been discontinued in the United States.^[4]

References[edit]

^ ^a ^b ^c ^d ^e ^f "Sulfonylureas, First Generation". Archived from the original on 11 January 2022. Retrieved 4 January 2022.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l "Chlorpropamide Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 4 January 2022.
^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 749. ISBN 978-0857114105.
^ "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Archived from the original on 3 March 2016. Retrieved 4 January 2022.

[Liv2022-1] ^ ^a ^b ^c ^d ^e ^f "Sulfonylureas, First Generation". Archived from the original on 11 January 2022. Retrieved 4 January 2022.

[AHFS2022-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ ^j ^k ^l "Chlorpropamide Monograph for Professionals". Drugs.com. Archived from the original on 4 March 2021. Retrieved 4 January 2022.

[BNF81-3] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 749. ISBN 978-0857114105.

[4] "Drugs@FDA: FDA-Approved Drugs". www.accessdata.fda.gov. Archived from the original on 3 March 2016. Retrieved 4 January 2022.

[1]

[2]

[3]

[4]